Join Us: Antibody-Drug Conjugates (ADCs) – Recent Advances in the Treatment of Solid Tumors
We are thrilled to announce that the Thailand Hub of Talents in Cancer Immunotherapy (TTCI), in collaboration with Chulalongkorn University and the Center of Excellence in Immunology, is organizing an upcoming exclusive webinar this June!
As targeted therapies continue to revolutionize oncology, Antibody-Drug Conjugates (ADCs) have emerged as one of the most powerful frontiers in precision medicine. We are highly honored to host Dr. Pipat Piewngam, PhD, Senior Principal Scientist from Summit Therapeutics, who will deliver a comprehensive deep dive into the recent clinical advances, breakthrough technologies, and future directions of ADCs in tackling solid tumors.
💡 Why You Can’t Miss This Session:
This webinar is highly recommended for researchers, oncologists, clinicians, and life science students who want to stay at the forefront of targeted cancer therapies. By joining us, you will:
Explore Next-Gen Targeted Therapy: Learn how ADCs combine the precision of monoclonal antibodies with the potency of cytotoxic drugs to eliminate tumor cells.
Analyze Clinical Breakthroughs: Gain insights into the latest research developments and clinical success stories of ADCs in solid tumor treatments.
Connect with Industry Expertise: Learn directly from a leading global pharmaceutical scientist driving therapeutic innovation.
Event Details At a Glance:
Topic: Antibody-Drug Conjugates (ADCs): Recent Advances in the Treatment of Solid Tumors
Date: Tuesday, 9 June 2026
Time: 09:00 AM – 10:00 AM
Speaker: Dr. Pipat Piewngam, PhD (Senior Principal Scientist, Summit Therapeutics)
Platform: Zoom Meeting
Meeting ID: 922 Jun 2026
Passcode: 211758